Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma

NCT01462695 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

NIH

Sponsor class

Conditions

Childhood Cerebellar Anaplastic Astrocytoma
Childhood Cerebral Anaplastic Astrocytoma
Childhood Cerebral Astrocytoma
Childhood Infratentorial Ependymoma
Childhood Mixed Glioma
Childhood Oligodendroglioma
Childhood Supratentorial Ependymoma
Recurrent Childhood Cerebellar Astrocytoma
Recurrent Childhood Cerebral Astrocytoma
Recurrent Childhood Ependymoma
Recurrent Childhood Subependymal Giant Cell Astrocytoma

Interventions

OTHER: Diagnostic Laboratory Biomarker Analysis
OTHER: Pharmacological Study
DRUG: Sunitinib Malate

Sponsor

National Cancer Institute (NCI)